Sorrento Therapeutics (SRNE) Competitors $0.0022 0.00 (-33.33%) (As of 09:30 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesOptions ChainSEC FilingsSustainabilityTrends SRNE vs. HEPA, CNSP, PRTG, UPXI, GHSI, BCDA, CELZ, FRTX, BFRI, and SNOAShould you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Hepion Pharmaceuticals (HEPA), CNS Pharmaceuticals (CNSP), Portage Biotech (PRTG), Upexi (UPXI), Guardion Health Sciences (GHSI), BioCardia (BCDA), Creative Medical Technology (CELZ), Fresh Tracks Therapeutics (FRTX), Biofrontera (BFRI), and Sonoma Pharmaceuticals (SNOA). These companies are all part of the "pharmaceutical products" industry. Sorrento Therapeutics vs. Hepion Pharmaceuticals CNS Pharmaceuticals Portage Biotech Upexi Guardion Health Sciences BioCardia Creative Medical Technology Fresh Tracks Therapeutics Biofrontera Sonoma Pharmaceuticals Hepion Pharmaceuticals (NASDAQ:HEPA) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation and community ranking. Is HEPA or SRNE more profitable? Sorrento Therapeutics' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Hepion PharmaceuticalsN/A -812.56% -207.31% Sorrento Therapeutics N/A N/A N/A Does the MarketBeat Community prefer HEPA or SRNE? Sorrento Therapeutics received 589 more outperform votes than Hepion Pharmaceuticals when rated by MarketBeat users. Likewise, 69.08% of users gave Sorrento Therapeutics an outperform vote while only 67.74% of users gave Hepion Pharmaceuticals an outperform vote. CompanyUnderperformOutperformHepion PharmaceuticalsOutperform Votes2167.74% Underperform Votes1032.26% Sorrento TherapeuticsOutperform Votes61069.08% Underperform Votes27330.92% Which has stronger earnings and valuation, HEPA or SRNE? Hepion Pharmaceuticals has higher earnings, but lower revenue than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHepion PharmaceuticalsN/AN/A-$48.93M-$4.38-0.16Sorrento Therapeutics$62.84M0.02-$572.84MN/AN/A Do insiders & institutionals have more ownership in HEPA or SRNE? 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 2.0% of Hepion Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate HEPA or SRNE? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor HEPA or SRNE? In the previous week, Sorrento Therapeutics had 1 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 1 mentions for Sorrento Therapeutics and 0 mentions for Hepion Pharmaceuticals. Hepion Pharmaceuticals' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score. Company Overall Sentiment Hepion Pharmaceuticals Neutral Sorrento Therapeutics Neutral Which has more volatility and risk, HEPA or SRNE? Hepion Pharmaceuticals has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. SummarySorrento Therapeutics beats Hepion Pharmaceuticals on 8 of the 11 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRNE vs. The Competition Export to ExcelMetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.21M$2.93B$5.07B$8.90BDividend YieldN/A1.91%4.99%4.07%P/E RatioN/A16.1687.8613.46Price / Sales0.02282.771,228.8287.66Price / CashN/A169.3839.5136.27Price / Book-0.044.436.946.30Net Income-$572.84M-$41.63M$119.12M$225.93M7 Day PerformanceN/A-4.73%-1.84%-1.32%1 Month PerformanceN/A-6.53%-3.65%0.60%1 Year PerformanceN/A25.63%31.64%26.23% Sorrento Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRNESorrento TherapeuticsN/A$0.00-33.3%N/A-93.4%$1.21M$62.84M0.00800Gap DownHEPAHepion PharmaceuticalsN/A$0.69flatN/A-78.1%$4.80MN/A0.0020CNSPCNS Pharmaceuticals1.6074 of 5 stars$0.14+12.1%$0.50+260.8%-99.9%$4.64MN/A0.005Gap DownHigh Trading VolumePRTGPortage Biotech2.1495 of 5 stars$4.39-3.9%$120.00+2,633.5%-84.3%$4.61MN/A0.006Upcoming EarningsUPXIUpexi1.4467 of 5 stars$4.42+0.5%$25.00+465.6%-78.0%$4.60M$80.68M0.00130GHSIGuardion Health SciencesN/A$3.22-2.1%N/A-43.4%$4.35M$12.25M0.6610Gap DownBCDABioCardia3.0529 of 5 stars$2.05+3.0%$25.00+1,119.4%-81.6%$4.35M$480,000.00-0.4916Analyst RevisionGap UpCELZCreative Medical Technology1.7223 of 5 stars$2.45-3.9%N/A-41.6%$4.29M$10,000.00-0.675Analyst RevisionPositive NewsGap DownFRTXFresh Tracks TherapeuticsN/A$0.72flatN/A-9.5%$4.27M$8.01M0.0020BFRIBiofrontera2.5806 of 5 stars$0.74-5.1%$7.00+845.8%-76.9%$4.10M$34.07M-0.3570Analyst RevisionGap DownSNOASonoma Pharmaceuticals0.8248 of 5 stars$2.94+3.5%N/A+1,381.5%$3.94M$12.73M0.00180 Related Companies and Tools Related Companies Hepion Pharmaceuticals Competitors CNS Pharmaceuticals Competitors Portage Biotech Competitors Upexi Competitors Guardion Health Sciences Competitors BioCardia Competitors Creative Medical Technology Competitors Fresh Tracks Therapeutics Competitors Biofrontera Competitors Sonoma Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SRNE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
